摘要
目的:为肺癌患者升白细胞药物的合理使用提供参考。方法:抽取浙江地区11家医院2009-2014年肺癌患者每年40 d的医嘱用药数据,对其销售金额、用药频度(DDDs)、日均费用(DDC)及科室分布情况等进行回顾性分析。结果:浙江地区11家医院2009-2014年肺癌患者升白细胞药物的销售金额及其在药品总销售金额中的占比总体呈下降趋势,由2009年的781 995.50元(3.28%)下降至2014年的626 792.80元(1.53%)。升白细胞药物销售金额比例排名前3位的科室分别为肿瘤科(29.00%)、放疗科(27.08%)和呼吸内科(9.93%)。2009-2014年销售金额排名前3位的药品分别为重组人粒细胞集落刺激因子、注射用复合辅酶和利可君片,DDDs排名前3位的分别为利可君片、小檗胺片和重组人粒细胞集落刺激因子;DDC排名前3位的药物为注射用复合辅酶、重组人粒细胞集落刺激因子和人粒细胞巨噬细胞集落刺激因子(2009-2013年)/利可君片(2014年)。结论:浙江地区11家医院肺癌患者升白细胞药物的使用呈逐年减少的趋势,疗效确切、价格适中的升白细胞药物在临床中占优势。
OBJECTIVE：To provide reference for rational use of leucocyte increasing drugs in patients with lung cancer.METHODS：The application of drugs in lung cancer patients in 40 d each year were collected from 11 Zhejiang hospitals during2009-2014,and then analyzed retrospectively in consumption sum,DDDs,DDC and department distribution,etc. RESULTS：The proportion of consumption sum of leucocyte increasing drugs in total consumption sum decreased generally in 11 Zhejiang hospital during 2009-2014,decreasing from 781 995.50 yuan in 2009（3.28%）to 626 792.80 yuan in 2014（1.53%）. Top 3 departments in the list of consumption sum of leucocyte increasing drugs were oncology department（29.00%）,radiotherapy department（27.08%）and respiratory medicine department（9.93%）. Top 3 drugs in the list of consumption sum during 2009-2014 were recombinant human granulocyte colony-stimulating factor,Coenzyme complex for injection and Leucogen tablets;top 3 drugs in the list of DDDs were Leucogen tablets,Berbamine tablet and recombinant human granulocyte colony-stimulating factor;Coenzyme complex for injection,recombinant human granulocyte colony-stimulating factor and human GM-CSF took the first three place in the list of DDC during 2009-2013,and Leucogen tablets were the top one in 2014. CONCLUSIONS：The application of leucocyte increasing drugs in lung cancer patients is decreasing year by year in 11 Zhejiang hospitals,and those with definite therapeutic efficacy and moderate price predominate clinical application predominate in the clinical practive.
出处
《中国药房》
CAS
北大核心
2016年第8期1020-1023,共4页
China Pharmacy
基金
浙江省药学会医院药学专项科研资助项目(No.2014ZYY13)
